Search results for "DMLA"
showing 10 items of 13 documents
Des données cliniques à la vie réelle : quelles preuves pour le devenir des patients DMLA ?
2016
Les oméga-3 dans la DMLA : quand la science confirme la clinique
2019
Evaluation of two treatment-modalities with ranibizumab for exudative age-related macular degeneration: inject and extend vs PRN (pro-re-nata)
2011
Evaluation of two treatment-modalities with ranibizumab for exudative age-related macular degeneration: inject and extend vs PRN (pro-re-nata). annual meeting of the association-for-research-in-vision-and-ophthalmology (ARVO)
Update on nutritionals and AMD
2012
Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS (T…
2016
Purpose : LUMINOUS™ (NCT01318941; initiated March 2011) is the largest, prospective, observational, global study in the field of medical retina. LUMINOUS™ is an ongoing 5-year study that is designed to evaluate the long-term safety, effectiveness, treatment patterns, and health-related quality of life associated with ranibizumab (RBZ) 0.5 mg treatment across all approved indications in 30,000 patients from routine clinical practice. We present the 1-year data from the French patients included in LUMINOUS™. Methods : Overall, 17, 545 adult patients with neovascular age-related macular degeneration (nAMD) were enrolled before March 2014; of these 9125 adult nAMD patients with a potential for …
Rétine et lipides : de l'analyse à la physiopathologie
2016
Revue; Rétine et lipides : de l'analyse à la physiopathologie. Colloque du Collège National de Biochimie-Biologie Moléculaire Médicale (CNBBMM)
Plasma omega 3 polyunsaturated fatty acids and macular pigment optical density in subjects at high risk for age-related macular degeneration: the Lim…
2016
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.; Purpose: In numerous epidemiological studies, omega 3 polyunsaturated fatty acids (PUFAs) have been associated with a decreased risk of age-related macular degeneration (AMD). Beyond their structural, functional and neuroprotective roles, omega 3 PUFAs may favor the retinal accumulation of lutein and zeaxanthin and thus increase macular pigment optical density (MPOD). We examined the associations of MPOD with plasma omega 3 PUFAs in subjects with at least one parent affected by neovascular AMD. Methods: The Limpia study is a double-blind, placebo controlled, prospective randomize…
Le rôle des lipides dans les maladies de l’œil
2012
Le rôle des lipides dans les maladies de l’œil
Actualités en micronutrition. Partie III : nouvelles données sur oméga-3 et angiogenèse
2017
Tout savoir sur le treat and extend : organisation et optimisation. Les Cahiers d'Ophtalmologie
2019
La dégénérescence maculaire liée à l’âge (DMLA) est actuellement la première cause de handicap visuel dans les pays développés chez les plus de 50 ans. Elle touche en effet environ 8% de la population française et plus de 25% des plus de 75 ans. La constatation d’une insuffisance de traitement lors d’un régime « réactif » a poussé les cliniciens à proposer d’autres types de régimes. Le « Treat and Extend » (T&E) est né de la volonté d’adapter les intervalles de retraitement des patients pour une prise en charge plus personnalisée.